Product
Phentolamine Ophthalmic Solution
Aliases
Nyxol, Nyxol®, Phentolamine Ophthalmic Solution 0.75%, phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
4 clinical trials
6 indications
Indication
Mesopic VisionIndication
Night Vision LossIndication
MydriasisIndication
DilationIndication
Dim Light Vision DisturbancesIndication
PresbyopiaClinical trial
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in Subjects Who Have Previously Had Keratorefractive Surgery and Have Decreased Visual Acuity Under Mesopic ConditionsStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy SubjectsStatus: Completed, Estimated PCD: 2020-12-23
Clinical trial
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision DisturbancesStatus: Completed, Estimated PCD: 2022-05-19
Clinical trial
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) With Pilocarpine Eye Drops in Subjects With PresbyopiaStatus: Completed, Estimated PCD: 2021-05-17